Patent · US Active

Zika virus RNA vaccines

US10124055B2 · kind B2 · utility

93Cited by

13References

26Claims

0Family size

Assignee

ModernaTX, Inc. · US

Inventors

Giuseppe Ciaramella · Sudbury, US
Sunny Himansu · Winchester, US
Eric Yi-Chun Huang · Boston, US
Tal Zaks · Newton, US

Key dates

Filing date	Aug 11, 2017
Grant date	Nov 13, 2018
Priority date	—
Expiry date	Aug 11, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates to Zika virus infection and the treatment thereof. The invention includes ribonucleic acid compositions, as well as methods of using the compositions for treating and preventing Zika virus infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.